Dimed Distribuidora de Medicamentos Toekomstige groei

Future criteriumcontroles 4/6

Dimed Distribuidora de Medicamentos zal naar verwachting groeien in winst en omzet met respectievelijk 23.4% en 10.8% per jaar. De winst per aandeel zal naar verwachting groeien met 27% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 13.6% zijn.

Belangrijke informatie

23.4%

Groei van de winst

27.0%

Groei van de winst per aandeel

Consumer Retailing winstgroei	29.8%
Inkomstengroei	10.8%
Toekomstig rendement op eigen vermogen	13.6%
Dekking van analisten	Low
Laatst bijgewerkt	14 Nov 2024

Recente toekomstige groei-updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 17

Recent updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Nov 17

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Nov 04

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Jul 12

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

May 27

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Apr 15

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Mar 25

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Jan 06

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Oct 23

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Aug 15

Winst- en omzetgroeiprognoses

BOVESPA:PNVL3 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (BRL Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	6,391	187	19	314	5
12/31/2025	5,702	145	-33	272	5
12/31/2024	5,151	122	6	322	2
9/30/2024	4,818	104	125	274	N/A
6/30/2024	4,712	91	190	321	N/A
3/31/2024	4,660	108	178	313	N/A
12/31/2023	4,461	93	157	297	N/A
9/30/2023	4,325	88	144	282	N/A
6/30/2023	4,211	83	175	325	N/A
3/31/2023	4,116	84	69	228	N/A
12/31/2022	3,990	86	24	205	N/A
9/30/2022	3,799	85	17	198	N/A
6/30/2022	3,584	83	21	189	N/A
3/31/2022	3,375	80	15	175	N/A
12/31/2021	3,225	79	-4	131	N/A
9/30/2021	3,135	79	-56	78	N/A
6/30/2021	3,032	79	-58	63	N/A
3/31/2021	2,878	62	-41	57	N/A
12/31/2020	2,819	56	46	131	N/A
9/30/2020	2,764	56	82	147	N/A
6/30/2020	2,754	62	34	90	N/A
3/31/2020	2,780	78	73	133	N/A
12/31/2019	2,725	77	75	129	N/A
9/30/2019	2,638	80	89	131	N/A
6/30/2019	2,562	79	65	106	N/A
3/31/2019	2,500	76	72	117	N/A
12/31/2018	2,432	75	51	110	N/A
9/30/2018	2,359	65	-20	45	N/A
6/30/2018	2,317	59	N/A	62	N/A
3/31/2018	2,282	59	N/A	29	N/A
12/31/2017	2,258	60	N/A	41	N/A
9/30/2017	2,238	60	N/A	78	N/A
6/30/2017	2,191	59	N/A	68	N/A
3/31/2017	2,146	57	N/A	104	N/A
12/31/2016	2,129	53	N/A	102	N/A
9/30/2016	2,095	53	N/A	92	N/A
6/30/2016	2,074	50	N/A	93	N/A
3/31/2016	2,043	50	N/A	76	N/A
12/31/2015	1,986	45	N/A	73	N/A
9/30/2015	1,963	44	N/A	59	N/A
6/30/2015	1,927	43	N/A	56	N/A
3/31/2015	1,916	48	N/A	26	N/A
12/31/2014	1,887	49	N/A	23	N/A
9/30/2014	1,835	50	N/A	29	N/A
6/30/2014	1,823	58	N/A	50	N/A
3/31/2014	1,786	55	N/A	66	N/A
12/31/2013	1,740	56	N/A	62	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei PNVL3 ( 23.4% per jaar) ligt boven de spaarquote ( 10.4% ).

Winst versus markt: De winst van PNVL3 ( 23.4% per jaar) zal naar verwachting sneller groeien dan de BR markt ( 12.6% per jaar).

Hoge groeiwinsten: De winst van PNVL3 zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van PNVL3 ( 10.8% per jaar) zal naar verwachting sneller groeien dan de markt BR ( 7.4% per jaar).

Hoge groei-inkomsten: De omzet van PNVL3 ( 10.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen PNVL3 zal naar verwachting over 3 jaar laag zijn ( 13.6 %).

Dimed Distribuidora de Medicamentos Toekomstige groei

Future criteriumcontroles 4/6

Belangrijke informatie

Recente toekomstige groei-updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Consensus EPS estimates fall by 30%

Price target decreased by 16% to R$14.38

Price target decreased by 8.5% to R$16.13

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Recent updates

Dimed S.A. Distribuidora de Medicamentos Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected

Third quarter 2024 earnings released: EPS: R$0.24 (vs R$0.16 in 3Q 2023)

Second quarter 2024 earnings released: EPS: R$0.034 (vs R$0.15 in 2Q 2023)

Consensus EPS estimates fall by 30%

Price target decreased by 16% to R$14.38

Price target decreased by 8.5% to R$16.13

First quarter 2024 earnings released: EPS: R$0.23 (vs R$0.12 in 1Q 2023)

Full year 2023 earnings: Revenues in line with analyst expectations

Upcoming dividend of R$0.068 per share at 1.9% yield

Third quarter 2023 earnings released: EPS: R$0.16 (vs R$0.12 in 3Q 2022)

Upcoming dividend of R$0.046 per share at 1.6% yield

Second quarter 2023 earnings released: EPS: R$0.15 (vs R$0.16 in 2Q 2022)

Price target decreased by 8.8% to R$17.65

Price target decreased by 9.1% to R$18.72

Full year 2022 earnings released: EPS: R$0.58 (vs R$0.53 in FY 2021)

No independent directors

Third quarter 2022 earnings released

Investor sentiment deteriorated over the past week

Investors Could Be Concerned With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Returns On Capital

Second quarter 2022 earnings released

These 4 Measures Indicate That Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Using Debt Extensively

Investors Shouldn't Be Too Comfortable With Dimed Distribuidora de Medicamentos' (BVMF:PNVL3) Robust Earnings

First quarter 2022 earnings: Revenues exceed analyst expectations

Price target decreased to R$22.85

No independent directors

Be Wary Of Dimed Distribuidora de Medicamentos (BVMF:PNVL3) And Its Returns On Capital

Full year 2021 earnings: EPS misses analyst expectations

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Seems To Use Debt Quite Sensibly

Investor sentiment deteriorated over the past week

The Returns On Capital At Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Don't Inspire Confidence

Price target decreased to R$30.20

Third quarter 2021 earnings released

Dimed S.A. Distribuidora de Medicamentos' (BVMF:PNVL3) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors

Investor sentiment deteriorated over the past week

Upcoming dividend of R$0.034 per share

Dimed Distribuidora de Medicamentos (BVMF:PNVL3) Is Reinvesting At Lower Rates Of Return

Dimed S.A. Distribuidora de Medicamentos(BOVESPA:PNVL4) dropped from Brazil Special Tag Along Stock Index

Dimed S.A. Distribuidora de Medicamentos announced that it expects to receive funding from Kinea Private Equity Investimentos S.A.

Dimed S.A. Distribuidora de Medicamentos has completed a Follow-on Equity Offering in the amount of BRL 1.036713 billion.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven